Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 19/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 5/20 | 0.65 |
| ▸ | ATM | Q13315 | 3/20 | 0.65 |
| ▸ | GLA | P06280 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487008 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL14413343 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL13088436 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL8959475 | 0.83 | CA12 (0.61) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL15898543 | 0.83 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL21120270 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HPGDKMT2AMAPTTSHR | |
| SCHEMBL28278861 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL10748020 | 0.82 | MAPT (0.59) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL4253087 | 0.82 | KDM4E (0.70) | KDM4EALDH1A1HPGDGAAATM | |
| SCHEMBL15898542 | 0.81 | KDM4E (0.78) | KDM4EALDH1A1HPGDGAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200083561-A1 | PHASE-CHANGE NANOPARTICLES FOR LI-ION BATTERY SAFETY | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-03-12 | — | — | US | claimed |
| US-20190097265-A1 | PHASE-CHANGE NANOPARTICLES FOR LI-ION BATTERY SAFETY | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-03-28 | — | — | US | claimed |
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20200083561-A1 | PHASE-CHANGE NANOPARTICLES FOR LI-ION BATTERY SAFETY | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190097265-A1 | PHASE-CHANGE NANOPARTICLES FOR LI-ION BATTERY SAFETY | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-03-28 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885ALDH1A1 1098/4885HPGD 2227/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885ALDH1A1 1098/4885HPGD 2227/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | KDM4E 1266/4885ALDH1A1 2238/4885HPGD 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.